NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as pa… [7186 chars]
Source: GlobeNewswire | Published: 2025-11-24T00:00:00Z
Credit: GlobeNewswire
